FreeStyle Libre Plus Bluetooth Transmitter Adjunct: Can This Improve Glucose Accuracy and Reduce Burden of Hypoglycaemia (FSL-M)
Primary Purpose
Type1 Diabetes Mellitus
Status
Withdrawn
Phase
Not Applicable
Locations
Kuwait
Study Type
Interventional
Intervention
FreeStyle Libre with MiaoMiao
FreeStyle Libre alone
Sponsored by
About this trial
This is an interventional supportive care trial for Type1 Diabetes Mellitus focused on measuring Hytpoglycemia, FreeStyle Libre, Flash Glucose Monitoring, MiaoMiao, Time in Range
Eligibility Criteria
Inclusion Criteria:
- T1DM for 12 months or more
- Age >21 years old
- Established user of FreeStyle Libre for ≥3 months
- HbA1C <12% (108mmol/mol)
- Able to check glucose with finger prick several times a day
Exclusion Criteria:
- Pregnancy or plans for pregnancy over the duration of the study
- Breast feeding
- Renal impairment with eGFR <30ml/minute/1.73m2
- Significant anaemia (males Hb<110g/L, females Hb <100g/L)
- Active malignancy
- Significant vision impairment
- Any significant illness- decision will be made by the PI or Co-I
- Not able to attend study visits
- Not able or not willing to participate in all study components
- Not able or not willing to give written informed consent
Sites / Locations
- Ali Aldibbiat
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
FSL-M
FSL-A
Arm Description
FreeStyle Libre + MiaoMiao Bluetooth adjunct with mobile application
FreeStyle Libre alone
Outcomes
Primary Outcome Measures
Mean absolute relative difference (MARD)
Comparing difference between glucose readings from the sensor in comparison to reference paired capillary glucose readings. This is to enable assessing accuracy of the intervention with FSL and MiaoMiao
Percentage time below 3.0mmol/L (54mg/dL)
This is to enable evaluating burden of hypoglycaemia. Analysis will be done on sensor glucose data
Percentage time in range 4-10mmol/L
This is to enable effect on time spent in normoglycaemia. Analysis will be done on sensor glucose data
Secondary Outcome Measures
Percentage time <4mmol/L (72mg/dL)
to evaluate general hypoglycaemia
Percentage time >10mmol/L
To evaluate hyperglycaemia
Change in HbA1C
To evaluate for any change in overall diabetes control
Rate of hypoglycaemia
number of episodes of hypoglycaemia
Rate of severe hypoglycaemia
number of episodes of severe hypoglycamia
Rate of device-related complications
This is specific for Libe and/or MiaoMiao
Change in dose of insulin
This will compare before and at end of each phase total daily insulin dose
Full Information
NCT ID
NCT04147637
First Posted
October 30, 2019
Last Updated
February 8, 2021
Sponsor
Dasman Diabetes Institute
1. Study Identification
Unique Protocol Identification Number
NCT04147637
Brief Title
FreeStyle Libre Plus Bluetooth Transmitter Adjunct: Can This Improve Glucose Accuracy and Reduce Burden of Hypoglycaemia
Acronym
FSL-M
Official Title
Crossover Randomized Controlled Trial of FreeStyle Libre Plus Bluetooth Transmitter Compared to FreeStyle Libre Alone in People With Type 1 Diabetes Mellitus. Can This Improve Accuracy and Reduce Burden of Hypoglycaemia
Study Type
Interventional
2. Study Status
Record Verification Date
October 2019
Overall Recruitment Status
Withdrawn
Why Stopped
due to irrelevancy of the idea given the advancement in the field and COVID-19 crisis
Study Start Date
October 14, 2020 (Anticipated)
Primary Completion Date
April 30, 2021 (Anticipated)
Study Completion Date
August 31, 2021 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Dasman Diabetes Institute
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Advanced glucose monitoring systems have revolutionized diabetes care and enabled people with diabetes to achieve better diabetes control with reduced risk of hypoglycaemia. Continuous glucose monitoring (CGM) systems provide real-time glucose monitoring and alarms when glucose approaches extreme readings (hypoglycaemia and hyperglycaemia) or when the change in glucose is rapid. All available CGM systems, except Dexcom G6, require daily calibrations with capillary glucose readings in order to attain accuracy of glucose readings. Decom G6 system is not widely accessible and only available in certain countries. Flash glucose monitoring systems (Flash) provide glucose readings when users actively scan their sensors. FreeStyle Libre (FSL) is the only Flash glucose monitoring system currently available in market. FSL is factory calibrated and sensors are ready to use after placement and initiation. The two main differences between Flash and CGM are user interaction and the alarm facility. While CGM provide real-time glucose readings, Flash is user-dependent for actively scanning and understanding the readings. Moreover, CGM systems provide alarms for low or high glucose and for rapid glucose changes, while Flash does not routinely provide alarms. This is particularly relevant when patients have impaired or lost hypoglycaemia awareness. CGM systems are costlier compared to Flash, which has contributed to the wider adoption of FSL.
Several Bluetooth adjuncts have been introduced to market for FSL. These devices attach to Libre sensor and connect to the user's mobile phone via Bluetooth. This enables continuous and real-time feed of glucose readings from the sensor to patient's mobile phone, which enables a wide range of customizable alarms for high and low glucose levels and for rapid glucose changes. This setup also enables calibration of Libre sensor with capillary glucose which, anecdotally, has been reported to improve sensor accuracy. None of these adjuncts have been validated clinically. FSL with Bluetooth adjunct such as MiaoMiao remain cheaper than current CGM options and could be more accessible in some countries than CGM. However, without robust evidence to support effectiveness and safety of such setup it is not possible to recommend this.
The Objective of this study is to determine whether FSL with Bluetooth Adjunct is superior to FSL alone in accuracy and reduction of hypoglycaemia burden.
Detailed Description
Study design:
Open-label, crossover, single center, randomized controlled trial of FreeStyle Libre with MiaoMiao Bluetooth transmitter adjunct with calibrations (FSL-M) compared to FreeStyle Libre alone (FSL-A) in people with T1DM.
Protocol summary:
Following informed written consent, subjects will be randomized to either FSL-M group using FSL with Miaomio and Tomato App premium version, or FSL-A with Libre Link app (stage 1). Subjects will spend 8 weeks in the assigned group followed by 2 weeks washout then subjects will switch over to the other group for further 8 weeks (stage 2).
While in FSL-M, subjects will be asked to calibrate FSL with daily capillary glucose values using Contour Plus, or on days 1, 2, 4, 8, 13 of sensor life. Alarms for low glucose (<3.9mmol/L, <70mg/dL) and high glucose (>13.9mmol/L, 250mg/dL) will be set in Tomato App.
7-point capillary glucose profiles will be carried out by subjects in both groups on days 2/3, 5/6, 9/10, 13/14 of each sensor life to enable paired comparison with sensor values.
Subjects will have routine labs at randomization, end of stage 1, and end of stage 2. All subjects will be asked to complete the following questionnaires: GOLD, Problem Areas in Diabetes (PAID) and Diabetes Quality of Life (DQOL) at randomization, at end of stage1 and end of stage 2. The group randomized to FSL-M at stage 1 will have qualitative interview at randomization, end of stage 1 and end of stage 2.
All adverse events will be collected including, but not limited to, all hypoglycaemia, diabetic ketoacidosis, hospital admissions for any reason, and device related skin reaction for the duration of the study in all subjects in both groups.
Data analysis will be carried out on glucose data retrieved from Libre view web-platform and Tomato App downloads in addition to Contour Plus meter downloads.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type1 Diabetes Mellitus
Keywords
Hytpoglycemia, FreeStyle Libre, Flash Glucose Monitoring, MiaoMiao, Time in Range
7. Study Design
Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Model Description
Randomized crossover study
Masking
None (Open Label)
Allocation
Randomized
Enrollment
0 (Actual)
8. Arms, Groups, and Interventions
Arm Title
FSL-M
Arm Type
Experimental
Arm Description
FreeStyle Libre + MiaoMiao Bluetooth adjunct with mobile application
Arm Title
FSL-A
Arm Type
Active Comparator
Arm Description
FreeStyle Libre alone
Intervention Type
Combination Product
Intervention Name(s)
FreeStyle Libre with MiaoMiao
Other Intervention Name(s)
FSL-M
Intervention Description
Use of FreeStyle Libre with MiaoMiao Bluetooth adjunct and mobile device application to enable calibration and alarms
Intervention Type
Device
Intervention Name(s)
FreeStyle Libre alone
Other Intervention Name(s)
FSL-A
Intervention Description
Use of standard FreeStyle Libre with Libre Link app and mobile phone scanning
Primary Outcome Measure Information:
Title
Mean absolute relative difference (MARD)
Description
Comparing difference between glucose readings from the sensor in comparison to reference paired capillary glucose readings. This is to enable assessing accuracy of the intervention with FSL and MiaoMiao
Time Frame
9 months
Title
Percentage time below 3.0mmol/L (54mg/dL)
Description
This is to enable evaluating burden of hypoglycaemia. Analysis will be done on sensor glucose data
Time Frame
9 months
Title
Percentage time in range 4-10mmol/L
Description
This is to enable effect on time spent in normoglycaemia. Analysis will be done on sensor glucose data
Time Frame
9 months
Secondary Outcome Measure Information:
Title
Percentage time <4mmol/L (72mg/dL)
Description
to evaluate general hypoglycaemia
Time Frame
9 months
Title
Percentage time >10mmol/L
Description
To evaluate hyperglycaemia
Time Frame
9 months
Title
Change in HbA1C
Description
To evaluate for any change in overall diabetes control
Time Frame
9 months
Title
Rate of hypoglycaemia
Description
number of episodes of hypoglycaemia
Time Frame
9 months
Title
Rate of severe hypoglycaemia
Description
number of episodes of severe hypoglycamia
Time Frame
9 months
Title
Rate of device-related complications
Description
This is specific for Libe and/or MiaoMiao
Time Frame
9 months
Title
Change in dose of insulin
Description
This will compare before and at end of each phase total daily insulin dose
Time Frame
9 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
21 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
T1DM for 12 months or more
Age >21 years old
Established user of FreeStyle Libre for ≥3 months
HbA1C <12% (108mmol/mol)
Able to check glucose with finger prick several times a day
Exclusion Criteria:
Pregnancy or plans for pregnancy over the duration of the study
Breast feeding
Renal impairment with eGFR <30ml/minute/1.73m2
Significant anaemia (males Hb<110g/L, females Hb <100g/L)
Active malignancy
Significant vision impairment
Any significant illness- decision will be made by the PI or Co-I
Not able to attend study visits
Not able or not willing to participate in all study components
Not able or not willing to give written informed consent
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ali Aldibbiat, MD PhD FRCP
Organizational Affiliation
Dasman Diabetes Institute
Official's Role
Principal Investigator
Facility Information:
Facility Name
Ali Aldibbiat
City
Kuwait City
ZIP/Postal Code
15462
Country
Kuwait
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
FreeStyle Libre Plus Bluetooth Transmitter Adjunct: Can This Improve Glucose Accuracy and Reduce Burden of Hypoglycaemia
We'll reach out to this number within 24 hrs